$270.36
+4.49 (+1.69%)
As of Mar 25, 9:33 PM ET ·
Day Range $264.29 — $270.95
52W Range $239.51 — $350.00

Performance

1D
1W
1M
3M -2.22%
6M -5.68%
1Y -15.84%
YTD -3.14%
Open$266.37
Previous Close$265.87
Day High$270.95
Day Low$264.29
52W High$350.00
52W Low$239.51
Volume
Avg Volume1.81M
Market Cap71.75B
P/E Ratio12.04
EPS$22.13
SectorHealth Care

Technical Indicators

Full analysis →
SMA 50 $277.76 Below
SMA 200 $292.58 Below
RSI (14) 61.1 Neutral
Trend Death Cross Bearish

Analyst Ratings

Strong Buy
33 analysts
27 Buy 6 Hold 0 Sell
Price Target -68.9% upside
Current
$270.36
Target
$84.17
$52.89 $84.17 avg $131.15

Key Financials

FY 2026 FY 2025 FY 2024
Revenue 270.36B 235.00B 20.79B
Net Income 5.86B 4.58B 3.82B
Profit Margin 2.2% 2.1% 18.4%
EBITDA 10.78B 8.90B 5.23B
Free Cash Flow 3.42B
Rev Growth +15.1% +15.1% +10.3%
Debt/Equity 0.75 0.75 0.24

Dividend

Dividend Yield2.22%
Annual Dividend$6.00
Payout Ratio27.0%
Frequencyquarterly
Ex-DividendApr 21, 2026
Pay DateMay 2, 2026

Recent Insider Activity

All Insiders →
Date Insider Type Shares Price Value
Mar 3 Jones Nicole S Sale 32,647 $288.91 $9.43M
Mar 3 Neville Everett Sale 5,670 $288.91 $1.64M
Nov 3 Cordani David Buy 157,935 $241.88 $38.20M
Oct 7 Evanko Brian C Exercise 56,550 $139.22 $7.87M
Oct 7 Evanko Brian C Sale 51,182 $300.00 $15.35M

About The Cigna Group

The Cigna Group is a global health services company that provides insurance and related products and services, headquartered in Bloomfield, Connecticut. The company operates through Evernorth Health Services, which includes pharmacy benefit management and care delivery services, and Cigna Healthcare, which offers medical, dental, disability, and life insurance. Cigna serves millions of customers worldwide through employer-sponsored plans, government programs, and individual coverage. The company focuses on improving health outcomes and affordability through integrated health services and innovative care delivery models.

Health Care Peers

Symbol Name Price Change P/E Mkt Cap
UNH UnitedHealth Group Inc $270.55 -0.64% 21.7 261.12B
ABT Abbott Laboratories $104.83 +0.74% 28.3 184.68B
ISRG Intuitive Surgical Inc $469.98 -0.41% 59.8 170.78B
SYK Stryker Corp $327.65 -0.26% 39.5 128.28B
MDT Medtronic Plc $87.89 +1.51% 24.1 111.30B
MCK Mckesson Corp $879.75 -0.25% 25.1 109.03B

CI Frequently Asked Questions

What does The Cigna Group do?
Cigna's largest revenue driver is its Evernorth division, which functions primarily as a pharmacy benefit manager — it negotiates drug prices on behalf of health plan sponsors, processes prescriptions through its Express Scripts network, and provides specialty pharmacy services. This makes it less dependent on medical insurance underwriting risk than traditional health insurers. The Cigna Healthcare segment underwrites employer-sponsored medical, dental, and disability coverage. The combination gives Cigna reach across both benefits administration and direct insurance.
Is CI stock a good investment?
Cigna's PBM-heavy model at Evernorth provides more predictable fee-based earnings than pure insurance underwriting, though pharmacy benefit management faces political scrutiny over drug pricing practices, which represents a regulatory risk. Medical cost inflation and the accuracy of actuarial assumptions drive profitability in the health insurance segment. The stock has traded at a discount to some healthcare peers, which investors attribute either to PBM regulatory uncertainty or a complex corporate structure. Consistent buybacks have reduced the share count steadily.
Who are The Cigna Group's main competitors?
UnitedHealth Group is the dominant integrated health insurer and PBM competitor, with its Optum arm mirroring Evernorth's structure. CVS Health, through its Aetna insurance and Caremark PBM divisions, is a direct rival across multiple Cigna segments. Elevance Health (formerly Anthem) competes in group health insurance. In standalone PBM, Prime Therapeutics also competes for employer and health plan contracts that Express Scripts pursues.
Does The Cigna Group pay dividends?
Cigna pays a quarterly dividend that has grown consistently since the company reinstated and then expanded its dividend program following the Express Scripts acquisition in 2018. With a yield typically around 2%, the dividend reflects a company balancing significant buyback activity alongside income returns. Management has stated a commitment to growing the dividend annually, supported by the recurring nature of PBM and health insurance cash flows.
How much does CI stock cost right now?
CI last closed at $270.36, up 1.69% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $239.51 and a high of $350.00. The current price represents 28% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What is the analyst consensus for CI?
Among 33 analysts covering CI, the consensus rating is Strong Buy — 27 rate it a buy, 6 hold, and 0 sell. The average price target sits at $84.17, implying 69% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
Does The Cigna Group make money?
The Cigna Group generated $270.36B in revenue during fiscal year 2026, with $5.86B reaching the bottom line as net income. The net profit margin of 2.2% reflects the competitive nature of its industry.
Is CI stock expensive based on earnings?
CI trades at a P/E ratio of 12.04 on trailing earnings of $22.13 per share. That's below the S&P 500 average, suggesting the market may see limited growth or is pricing in sector-specific risks. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
Is CI stock going up or down?
Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -2.22% (3M), -5.68% (6M), -15.84% (1Y), -3.14% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether CI is outperforming or lagging the broader market.